head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing
ISSN: 1312-773X (Online)
Issue: 2017, vol. 23, issue 4
Subject Area: Medicine
DOI: 10.5272/jimab.2017234.1713
Published online: 06 October 2017

Original article

J of IMAB 2017 Oct-Dec;23(4):1713-1717
Kalina Stoyanova1 ORCID logo Corresponding Autoremail, Tatyana Cvetkova1 ORCID logo, Stela Dragomanova2 ORCID logo, Stoyan P. Pavlov3 ORCID logo,
1) Department of Infectious Diseases, Parasitology and Dermatovenereology, Faculty of Medicine, Medical University – Varna, Bulgaria
2) Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University – Varna, Bulgaria
3) Department of Anatomy, Histology and Embryology, Faculty of Medicine, Medical University – Varna, Bulgaria.

The effective etiological antiparasitic treatment fulfils two major goals - to cure the infected patient and to terminate its role as an epidemiologically relevant source of infection.
The purpose of this study is to evaluate the effectiveness of the pharmacotherapy against the most common intestinal helminthic and protozoal infections diagnosed in Varna region.
Material and Methods: 879 patients with laboratory confirmed intestinal parasitoses were treated etiologically with the established anthelminthic and antiprotozoal agents. Mandatory and active post-treatment laboratory monitoring served as the basis for the assessment of the therapy effectiveness.
Results: Enterobiasis has the highest prevalence of the intestinal parasitic infections with estimated treatment success of 94,7% at the end of the mandatory period and nearly 100% at the end of our monitoring. The significantly greater rate of relapses was registered among the patients with the two most common protozoal invasions – Giardiasis (9,5%) and Blastocystosis (6,7 %). Our analysis established that the main factors limiting the effective antiparasitic pharmacotherapy are extraneous, i.e. independent of the pharmacological properties of the agent or parasite’s biology. The most prominent reasons for therapy failure are poor or missing compliance to the therapy regimen, inadequate form or dosage of the medication, unrecognized source of (re)invasion, etc.
In conclusion, the collaboration between the general-practitioners, clinical parasitologists and respectively the patients themselves is crucial for achieving an effective therapy and the resultant control of the intestinal parasitoses.

Keywords: intestinal parasitic diseases, Enterobiasis, Giardiasis, antiparasitic agents, treatment effectiveness,

pdf - Download FULL TEXT /PDF 572 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Stoyanova K, Cvetkova T, Dragomanova S, Pavlov SP. Factors limiting the effectiveness of intestinal parasitoses’ pharmacotherapy. J of IMAB. 2017 Oct-Dec;23(4):1713-1717. DOI: 10.5272/jimab.2017234.1713

Corresponding AutorCorrespondence to: Dr. Kalina Stoyanova, Department of Infectious Diseases, Parasitology and Dermatovenereology, Faculty of Medicine, Medical University – Varna; 55, Prof. Marin Drinov Str., Varna 9000, Bulgaria; E-mail: drkalinasto@gmail.com

1. Stoyanova K, Cvetkova T, Pavlov S, Todorov S, Gospodinova M. Prevalence of Intestinal and Non-intestinal Parasitoses in Varna region for 2013-2015 year: data from outpatient parasitological testing. Scr Sci Medica. 2016;48(2):45-49. [CrossRef]
2. Chakarova B. Giardiasis in humans - clinical, epidemiological and therapeutical aspects. Trakia University (Stara Zagora). 2011. [in Bulgarian]
3. Angelov I. Blastocystosis - the unknown parasitosis. Gramma (Pleven). 2010. [in Bulgarian]
4. Harizanov R, Rajnova I, Kaftandjiev I, Jordanova D, Marinova I. Soil – transmitted helminth infections in Bulgaria: a retrospective study of some epidemiological features. Probl Infect Parasit Dis. 2013; 41(2):32-5.
5. Vuchev D, Stoyanova K. Rational chemotherapy of intestinal parasitoses - practical aspects. Exotic Infectous and Parasitict Disseases. HIV AIDS Co-Infect. 2015; 94-8. [in Bulgarian]
6.The International Pharmacopoeia. Sixth Edition. WHO. 2016 [Internet]
7. Drugs for Parasitic Infections. Treatment Guidelines from The Medical Letter. 2013; 11(Suppl):e1-e31. [Internet]  
8. Vuchev D. Handbook of parasitic diseases. Five plus. Sofia; 2001. [in Bulgarian]
9. WHO model list of essential medicines: 17th list, March 2011. Geneva: World Health Organization. IRIS. [Internet]
10. Medicinal products authorized for use in the Republic of Bulgaria. The BDA Bulletin online. 2017. [in Bulgarian] [Internet].
11. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. [Internet]
12. Venables WN, Ripley BD. Modern Applied Statistics with S. 4th ed. Series: Statistics and Computing. Springer New York. 2002. [CrossRef]
13. RHI - Varna. Annual report of RHI - Varna for 2012. Varna, Bulgaria. 2013. [in Bulgarian]  [Internet]
14. RHI - Varna. Annual report of RHI - Varna for 2013. Varna, Bulgaria. 2014. [in Bulgarian]  [Internet]
15. RHI - Varna. Annual report of RHI - Varna for 2014. Varna, Bulgaria. 2015. [in Bulgarian]  [Internet]
16. RHI - Varna. Annual report of RHI - Varna for 2015. Varna, Bulgaria. 2016. [in Bulgarian]  [Internet]
17. Escobedo A, Hanevik K, Almirall P, Cimerman S, Alfonso M. Management of chronic Giardia infection. Expert Rev Anti Infect Ther. 2014 Sep;12(9):1143-57. [PubMed] [CrossRef]
18. Tan KS. New insights on classification, identification, and clinical relevance of Blastocystis spp. Clin Microbiol Rev. 2008 Oct;21(4):639-65. [PubMed] [CrossRef]..

Received: 05 June 2017
Published online: 06 October 2017

back to Online Journal